Skip to main content

Increasing FDA approval for thyroid cancer drug is expected to present profitable market opportunities

 


Thyroid disorder therapy is a fast-growing area of treatment for people suffering from this condition. The thyroid gland is responsible for regulating metabolism and temperature, with control through the use of the thyroid gland located in the neck just below the voice box. A person suffering from Thyroid disorder have signs and symptoms such as weight gain, fatigue, depression, and constipation. Thyroid Dysfunction may be caused by many factors, and the causes and symptoms are different in every person. Thyroid disease is a highly treatable condition if diagnosed early enough, although treatment options will vary from person to person depending on their age, overall health, and underlying health problems.

The growing prevalence of thyroid disorder around the globe is a prime factor driving the market growth of thyroid disorder therapy. According to the American Thyroid Association (ATA), an estimated 20 million Americans have some form of thyroid disease. Up to 60 percent of those with thyroid disease are unaware of their condition. Women are five to eight times more likely than men to have thyroid problems. The increasing geriatric population coupled with the rise in the global healthcare expenditure is again expected to augment the market growth of thyroid disorder therapy.

North America is expected to gain significant growth over the forecast period and this is attributed to the increasing prevalence of thyroid cancer coupled with the continuous FDA approval for the new and advanced drug. For instance, in December 2020, the Food and Drug Administration approved pralsetinib (GAVRETO, Blueprint Medicines Corporation) for RET-altered thyroid cancers. Moreover, increasing spending by the government on cancer treatment for improving patient care is further anticipated to augment the regional market growth of thyroid disorder therapy over the forecast period.

Key Developments:

1.      In October 2020, BDR Pharmaceutical announced the launch of 4 mg and 10 mg of Lenvatinib under the brand name BDFOIE for the treatment of differentiated thyroid cancer, advanced liver cancer, and advanced kidney cancer.

2.      In July 2020, Roche and its Genentech subsidiary announced its partnership with Blueprint Medicines to develop and commercialize the once-daily oral cancer drug pralsetinib in most of the world.

3.      In May 2018, FDA has approved Novartis’ combination treatment dabrafenib (Tafinlar) and trametinib (Mekinist) for the treatment of BRAF V600 mutation-positive anaplastic thyroid cancer (ATC) that cannot be removed by surgery or is metastatic.

 

 

 

 

 

Comments

Popular posts from this blog

The Global Autoclave Equipment Market Continues To Grow Owing To the Rising Demand from Healthcare Sectors for Sterilizing Medical Equipment to Ensure the Safety of the Post-Surgical Period

  Autoclave equipment is the most popular sterilization method in the industry and is used for many applications including the manufacture of food products. It is widely used in the foodservice industry to sterilize and cleanse equipment used in the process of preparing and serving food. The autoclave is the abbreviated form of autolysis which means oxidation. Autoclaves have various parts including an electric motor, a condenser, and a burner. Autoclave equipment includes vials for sealing the autoclave, a glass or plastic container that has been lined with wax or plastic, and the appropriate autoclave equipment accessories such thermometer for measuring the temperature of the autoclave. All modern steam sterilizing equipment & autoclave machines provide a much-refined workflow experience, which makes you reconsider whether or not steam sterilizing is all it can be. A wide range of sterilization methods is used for sterilizing your medical and laboratory specimen so the right ...

Biologics Market Increasing Prevalence of Chronic Diseases to Augment Growth of the market

  A  biologic  drug ( biologics ) is a product that is produced from living organisms or contains components of living organisms.  Biologic  drugs are widely used to prevent, diagnose, treat, or cure a variety of diseases, including infectious diseases, autoimmune disorders, chronic kidney disease, and cancer. Market Dynamics In the recent past, several novel biopharmaceutical products were approved by major regulatory bodies and major players in the market have launched various novel and innovative biopharmaceutical products. Rapid approvals and launches of novel products in the market are expected to be major drivers for growth of the biologicsmarket . 

Treprostinil Drugs Market - High Prevalence of Pulmonary Arterial Hypertension and R&D of New Formulations of Treprostinil to Augment Growth of market

  Treprostinil is an antihypertensive agent used to treat patients with pulmonary arterial hypertension. It can also be used in the treatment of Degos disease, an extremely rare disorder in which small and medium sized arteries become blocked (occlusive arteriopathy), restricting the flow of blood to affected areas. Market Dynamics High prevalence of pulmonary arterial hypertension is expected to propel growth of the treprostinil drugs market . For instance, according to the study, ‘High Geographic Prevalence of Pulmonary Artery Hypertension: Associations with Ethnicity, Drug Use, and Altitude’, published in February 2020, in the journal Pulmonary Circulation, the overall pulmonary arterial hypertension incidence was 14 cases per million and the annual period prevalence of pulmonary arterial hypertension was 93 cases per million. Decline in new prescriptions for treprostinil-based products is expected to hinder growth of the treprostinil drugs market. For instance, United The...